Why the study?
Reports of familial hyperaldosteronism type 1 in pregnancy are limited, and treatment guidelines for this condition are lacking.
How should familial hyperaldosteronism type 1 be managed during pregnancy to optimize maternal and fetal outcomes?
How should familial hyperaldosteronism type 1 be managed during pregnancy to optimize maternal and fetal outcomes?
Answers are grounded in this paper and cite their sources.
This systematic review provides a practical algorithm for managing familial hyperaldosteronism type 1 in pregnancy, recommending dexamethasone withdrawal in the first trimester and careful reintroduction if hypertension recurs.
PURPOSE: Familial hyperaldosteronism type 1 (FH-1) is a rare autosomal dominant form of primary aldosteronism, which features a marked phenotypic heterogeneity, ranging from mild to severe forms of arterial hypertension that can be complicated by stroke and cardiovascular events at a young age. As affected patients usually reach the fertile age, transmission of the disease to offspring is common. Notwithstanding this, reports of FH-1 in pregnancy are limited and there is a lack of treatment guidelines. METHODS AND RESULTS: We searched the PubMed and EuropePMC databases with a PICO strategy to retrieve available information on management of FH-1 patients during pregnancy. We could identify seven relevant articles, which are herein reviewed. CONCLUSION: Based on available information on pathophysiology and treatment of FH-1 in pregnancy, recommendations for the rational management of FH-1 in pregnancy are provided.
No takes yet. Share an insight, caveat, or question.
Sanga et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: